A Prospective Cohort for ex Vivo Cure Studies With Chronic HIV Infected Patients in the Netherlands

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

35 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-26

Study Completion Date

2034-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective non-interventional cohort study at Erasmus MC of adult chronic HIV infected patients of ≥18 years of age who initiate antiretroviral therapy in routine care.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Netherlands Cohort Study on Acute HIV Infection

NCT05728996

Acute HIV Infection

RECRUITING

Acute HIV Infection Observational Study

NCT00296660

HIV Infections

COMPLETED

HIV-1 Resistance at Screening for HIV Prevention Studies

NCT01204814

HIV

COMPLETED

The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment

NCT00857350

HIV Positive Opioid Dependence Opioid Agonist Treatment +1 more

COMPLETED

4-Day-A-Week Treatment Plan for HIV Infected Adolescents

NCT00068809

HIV Infections

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

HIV cannot be cured with the current treatment armamentarium. A reservoir of latently HIV infected long lived CD4+T-cells is present in patients with HIV that are not affected by antiretroviral therapy. The evolution of this reservoir after therapy initiation is ill understood, as are the potential strategies to eradicate this reservoir. This study aims to anticipate on future HIV cure strategies by building a cohort to study ex vivo the reservoirs of HIV patients, the obstacles to cure HIV, and new therapeutic compounds and strategies.

Main study parameters/endpoints:

1. Change in viral reservoir size after antiretroviral treatment initiation.
2. Evolution of phenotypical and functional aspects of the anti-HIV host immune responses.
3. Ex vivo activity of established and novel HIV latency reversing agents.
4. Variance in HIV reservoir and host immunity between HIV subtypes and clinical variables.

A project from the Erasmus MC HIV Eradication Group (EHEG).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections HIV-1-infection HIV-2 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>18 years.
* Confirmed HIV-1 or HIV-2 infection
* Judged willing to initiate and adhere to cART by the HIV physician.

Exclusion Criteria

* Inability to place venous catheters to draw blood.
* Major comorbidities:

1. Severe symptomatic anemia or recent symptomatic cardiovascular event (un-stable angina pectoris, decompensated heart failure, myocardial infarction).
2. The inability to participate due to any other relevant social, environmental,psychological, factors or according to the HIV treating physician's judgement.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No